Innate Pharma Sa Class A · EURONEXT:IPH

Innate Pharma Sa Class A — Investor Presentation (November 2022)

36 slides from Innate Pharma Sa Class A's investor presentation, November 2022

  1. Slide 1: Company Overview

    Company Overview November 2022 PARIS: IPH.PA NASDAQ: IPHA © 2020 Innate Pharma. All rights reserved.

  2. Slide 2: Disclaimer on Forward-Looking Information and Risk Factors

    Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document co

  3. Slide 3: A Leading Company in the Field of Innate Immunity

    A Leading Company in the Field of Innate Immunity • Global, clinical-stage oncology-focused MARSEILLE FRANCE biotech company. ROCKVILLE MARYLAND • Scientific excellence in the field of innate immunity with expertise in natural killer cell biology and antibody engineering. • Focused pipeline of antib

  4. Slide 4: Scientific Innovation Drives Our Strategy

    Scientific Innovation Drives Our Strategy We aim to harness our scientific know-how in innate immunity and antibody engineering to develop oncology products that improve the lives of patients Drive near-term Advance our Build a sustainable value with innovative R&D business through Lacutamab pipelin

  5. Slide 5: Strong Science + Strong Partnerships = Robust Pipeline

    Strong Science + Strong Partnerships = Robust Pipeline Validated Strong Track Robust Science Record of Pipeline in high-impact Collaborations with innovative publications pre-clinical and with industry and clinical assets academia 5

  6. Slide 6: Innate's Approach: Harnessing Innate Immunity in Cancer

    Innate’s Approach: Harnessing Innate Immunity in Cancer Choosing the right targets to leverage the body’s immune response Priming and activation (APCs and T cells) Engage NK cells 1 towards tumor Cancer antigen presentation (DCs) Lacutamab (KIR3DL2) Lymph node Trafficking of (NKp46) T cells to tumor

  7. Slide 7: Our Robust Pipeline of Proprietary & Partnered Assets

    Our Robust Pipeline of Proprietary & Partnered Assets Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Comments Sézary syndrome TELLOMAK (FDA FAST TRACK/EMA PRIME DESIGNATION) Preliminary Phase 2 data at ASH 2022 Mycosis Fungoides TELLOMAK Preliminary Phase 2 data presented EORTC 2022

  8. Slide 8: Driving Our Proprietary Portfolio

    Driving Our Proprietary Portfolio

  9. Slide 9: Lacutamab: Lead Proprietary Asset

    LACUTAMAB Lacutamab: Lead Proprietary Asset • Lacutamab under development for the treatment of First-in-class anti-KIR3DL2 humanized various forms of T-cell lymphomas (TCL) cytotoxicity-inducing antibody lacutamab • Compelling Phase 1 data in Sézary syndrome (SS), published in Lancet Oncology KIR3DL

  10. Slide 10: Development Informed by Target Expression

    LACUTAMAB Development Informed by Target Expression KIR3DL2 EXPRESSION INCIDENCE Major markets (US, EU5, Japan), 2025 SEZARY SYNDROME • >90% of patients express target* ~80–200 patients1 • All tissues involved (skin, blood and lymph nodes) MYCOSIS FUNGOIDES 2,200–4,000 patients1 • ~50% of patients e

  11. Slide 11: Developing New Standard of Care in KIR3DL2-Expressing T-Cell Lymphomas

    LACUTAMAB Developing New Standard of Care in KIR3DL2-Expressing T-Cell Lymphomas Sezary Cutaneous Syndrome T-Cell Lymphoma Fast to market approach (CTCL) Niche indication with high unmet need Mycosis Fungoides Expand potential beyond SS Explore impact of KIR3DL2 expression on clinical outcome Periph

  12. Slide 12: Compelling Phase 1 Results

    LACUTAMAB Compelling Phase 1 Results FDA Fast Track Designation granted based on these results Sézary Syndrome Subgroup (n=35) Total 44 patients with CTCL ≥ 2 lines of therapy Best change in mSWAT as compared to baseline Best Global Response • 25 (incl. 20 SS) in dose escalation (intra-patient dose

  13. Slide 13: TELLOMAK Phase 2 Study in Two CTCL Subtypes

    LACUTAMAB TELLOMAK Phase 2 Study in Two CTCL Subtypes Potential for Sézary syndrome cohort to serve as pivotal trial Sézary syndrome (N~60) Mycosis Fungoides (N~100) ≥ 2 prior systemic therapies ≥ 2 prior systemic therapies Cohort 1 Cohort 2# Cohort 3# All Comers* All comers, SS, must include KIR3DL

  14. Slide 14: Encouraging Preliminary Results in KIR3DL2-Expressing Mycosis Fungoides Cohort of TELLOMAK trial

    LACUTAMAB Encouraging Preliminary Results in KIR3DL2-Expressing Mycosis Fungoides Cohort of TELLOMAK trial Stage 1 results in MF patients with at least 2 prior line therapy Cohort 2 Cohort 3 KIR3DL2 expressors (n=21) KIR3DL2 non expressors (n=18) Skin Skin N % [95%CI] N % [95%CI] Global ORR 6 (2CR;

  15. Slide 15: ASH abstract - Preliminary lacutamab Sézary syndrome Phase 2 data

    LACUTAMAB ASH abstract - Preliminary lacutamab Sézary syndrome Phase 2 data Preliminary Sézary syndrome Phase 2 TELLOMAK data, final data due in 2023 Patient baseline characteristics 37 post mogamulizumab patients with advanced, highly refractory and heavily pre-treated disease 6 median lines of pri

  16. Slide 16: Initiating Data-Driven Strategy in PTCL

    LACUTAMAB Initiating Data-Driven Strategy in PTCL N O W N E X T S T E P S RELAPSED SETTING 03 FRONTLINE Highest unmet medical need; two- Driven by data in the relapsed setting pronged approach: to advance into earlier lines • Monotherapy (Phase 1b study in H2 2021) • Combination with CHOP 02 • Combi

  17. Slide 17: Developing a New Standard of Care Across KIR3DL2 Expressing T-Cell Lymphomas

    LACUTAMAB Developing a New Standard of Care Across KIR3DL2 Expressing T-Cell Lymphomas Cutaneous T-Cell Lymphoma (CTCL) Peripheral T-Cell Lymphoma (PTCL) Phase 2 TELLOMAK Trial Multi-trial Strategy Sézary Syndome Mycosis Fungoides From Relapsed to Frontline PTCL 80-200 patients 2,200-4,400 patients

  18. Slide 18: Next-Generation Assets: NK Cell Engagers

    Next-Generation Assets: NK Cell Engagers

  19. Slide 19: NK Cells Offer Unique Cancer-Fighting Abilities

    ANKETTM NK Cells Offer Unique Cancer-Fighting Abilities NK SPECIFICITY • NK cells are not expected to produce a cytokine storm NK cells in • NKp46 is the most specific activating receptor of NK cells periphery N K p 4 6 E X P R E S S I O N S TA B I L I T Y NKp46 • Unlike many other activating recept

  20. Slide 20: ANKET: Innate's Proprietary NK Cell Engager Platform

    ANKETTM ANKET™: Innate’s Proprietary NK Cell Engager Platform ANKET™ Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46 is a versatile, fit-for-purpose technology Provides proliferation and activation signals that is creating

  21. Slide 21: ANKET molecules have the potential to strongly control tumor proliferation

    ANKETTM ANKET™ molecules have the potential to strongly control tumor proliferation via the proliferation and activation of NK cells NK cells are proven anti-tumor cells Innate Pharma differentiated MoA Strong preclinical activity Tetraspecific ANKET Cytokine production Tumor cell NK cell Killing NK

  22. Slide 22: Two molecules from Innate ANKET engine selected by Sanofi

    ANKETTM Two molecules from Innate ANKETTM engine selected by Sanofi Anti-CD123 IPH6101/SAR’579 currently in Phase 1 in AML ; Anti-BCMA IPH6401/SAR’514 progressing toward IND Multispecific antibody engineering targeting a tumor antigen, NKp46 and CD16a IPH6101/SAR’579 IPH6401/SAR’514 €13M milestone p

  23. Slide 23: CD123 tri-specific SAR'579/IPH6101 Demonstrates Potent Antitumor Activity Against AML

    ANKETTM CD123 tri-specific targeted SAR’579/IPH6101 Demonstrates Potent Antitumor Activity Against AML and Favorable Safety Profile SAR443579/IPH6101 kills AML cells resistant to ADCC SAR443579/IPH6101 induce CD123-expressing cell depletion in NHP with minor cytokine release ADCC-sensitive AML cells

  24. Slide 24: Optimal Efficacy Requires All Arms in Tetra-specific ANKET

    ANKETTM Optimal Efficacy Requires All Arms in Tetra-specific ANKET™ Demonstrate Superiority in Preclinical Model of Tumors Solid tumor models Disseminated tumor models IND filing in 2023 TAg: Tumor antigen *ADCC-enhanced mAb 24

  25. Slide 25: Different Receptors have Different Effects on NK cells

    ANKETTM Different Receptors have Different Effects on NK cells NKG2D NKp46 CD16 IL-2Rb IL-2Rg DAP10 CD3ζ, FcRγ # • NK cell activation + • NK cell activation +++ • Proliferation +++ • cytotoxicity • cytotoxicity • cytokines and chemokines Adapted from Lanier, Nature Immunol 2008; Vivier et al., Scien

  26. Slide 26: Building a Sustainable Business

    Building a Sustainable Business

  27. Slide 27: Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams

    MONALIZUMAB Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams A strong potential in association in the NSCLC NK Cell Monalizumab blocks the Late-stage Clinical Trial Highlights: NKG2A receptor on both NK cells and cytotoxic • AstraZeneca initiated Phase 3 trial, PACIFI

  28. Slide 28: Monalizumab: Early NSCLC

    MONALIZUMAB Monalizumab: Early NSCLC Phase 3 program underway, sponsored by AstraZeneca, for patients with unresectable, Stage III NSCLC NSCLC Phase 3 in unresectable, Stage III NSCLC STAGE I STAGE II STAGE III STAGE IV Phase 2 NeoCOAST* Phase 2 COAST* Stg I-IIIA NSCLC Unresect. Stg III NSCLC monali

  29. Slide 29: Monalizumab: NSCLC

    MONALIZUMAB Monalizumab : NSCLC 2021 and AACR 2022 data presentations provide rationale for further exploration in NSCLC NeoCOAST: open-label, randomized, Phase 2, multidrug platform study of COAST: Phase 2 study of durvalumab alone or in combination with novel agents in neoadjuvant durvalumab alone

  30. Slide 30: Adenosine Pathway: IPH5201 (anti CD39) and IPH5301 (anti CD73)

    ADENOSINE Adenosine Pathway: IPH5201(anti CD39) and IPH5301 (anti CD73) Clinical trials underway IPH5201* (anti CD39): Phase 1 clinical trial design Combination Monotherapy IPH5201 IPH5201 + durvalumab PART 1 PART 2 IPH5301 (anti CD73): Design of the Phase 1 clinical trial ISS CHANCES Extension Dose

  31. Slide 31: IPH5201: Preclinical Data

    IPH5201 IPH5201*: Preclinical Data Significant tumor responses observed in response to treatment with PD-1 inhibitors and ADCC-inducing antibodies, as well as with immunogenic chemotherapy, compared to responses to these agents in wild-type mice Sources: Perrot et al., Cell Reports 2019 *2018 collab

  32. Slide 32: IPH5301: Preclinical Data

    IPH5301 IPH5301: Preclinical Data IPH5301 more potent in restoring CD4+ and CD8+ T-cell proliferation in an ATP-suppression assay, than the most advanced clinical candidates CD4+ T cells + CD8+ T+ cells C D 4 T c e lls C D 8 T c e lls c o n tr o l) * * * r a te 1 0 0 * * * * 1 0 0 * * * 8 0 8 0 P r

  33. Slide 33: Catalysts and Summary

    Catalysts and Summary 5 innate pharma Naa

  34. Slide 34: Upcoming catalysts

    Upcoming catalysts Delivering across our strategic objectives • Monalizumab PACIFIC-9 | Phase 3 readout • Monalizumab NeoCOAST-2 | Phase 2 readout • IPH5201 (CD39) MATISSE | Phase 2 readout • IPH6501 ANKETTM (CD20) | IND Filing • IPH6501 ANKETTM (CD20) | Phase 1 data • IPH6401 ANKETTM (BCMA) | IND •

  35. Slide 35: Early R&D Focus to Drive Value Through Later Stage Partnerships

    Early R&D Focus to Drive Value Through Later Stage Partnerships Lacutamab R&D pipeline Partnerships • TELLOMAK preliminary data • Advancing proprietary CD20 tetra- • Phase 3 monalizumab presentations in MF and SS in specific NK cell-targeted platform collaboration with AstraZeneca 2022 and portfolio

  36. Slide 36: Thank You

    THANK YOU www.innate-pharma.com PARIS: IPH.PA NASDAQ: IPHA © 2020 Innate Pharma. All rights reserved.

Innate Pharma — Investor Presentation (November 2022) on 6ix